These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32991694)

  • 1. Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020.
    Ferrannini G
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):341-342. PubMed ID: 32991694
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
    Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
    Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
    Qiu M; Ding LL; Zhang M; Lin JH; Gu JS; Zhou X; Tang YX; Wei XB; Liu SY
    Pharmacol Res; 2020 Nov; 161():105175. PubMed ID: 32860942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
    Xiang B; Zhao X; Zhou X
    Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
    Nassif ME; Kosiborod M
    Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
    [No Abstract]   [Full Text] [Related]  

  • 10. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
    Pagidipati NJ; Lopes RD
    J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
    Testani JM; Inzucchi SE; Voors AA
    Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
    Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 14. SGLT2i: beyond the glucose-lowering effect.
    Ni L; Yuan C; Chen G; Zhang C; Wu X
    Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
    Shehadeh N; Raz I; Nakhleh A
    Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
    [No Abstract]   [Full Text] [Related]  

  • 16. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 18. SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
    Ghaffar ZA; Anwar S; Rizvi SW
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):195. PubMed ID: 30700368
    [No Abstract]   [Full Text] [Related]  

  • 19. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
    Bertero E; Prates Roma L; Ameri P; Maack C
    Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.